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Abstract: The unique properties of supercritical fluids, in particular supercritical carbon dioxide
(CO2), provide numerous opportunities for the development of processes for pharmaceutical
applications. One of the potential applications for pharmaceuticals includes microencapsulation and
nanoencapsulation for drug delivery purposes. Supercritical CO2 processes allow the design and
control of particle size, as well as drug loading by utilizing the tunable properties of supercritical CO2
at different operating conditions (flow ratio, temperature, pressures, etc.). This review aims to provide
a comprehensive overview of the processes and techniques using supercritical fluid processing
based on the supercritical properties, the role of supercritical carbon dioxide during the process,
and the mechanism of formulation production for each process discussed. The considerations for
equipment configurations to achieve the various processes described and the mechanisms behind the
representative processes such as RESS (rapid expansion of supercritical solutions), SAS (supercritical
antisolvent), SFEE (supercritical fluid extraction of emulsions), PGSS (particles from gas-saturated
solutions), drying, and polymer foaming will be explained via schematic representation. More recent
developments such as fluidized bed coating using supercritical CO2 as the fluidizing and drying
medium, the supercritical CO2 spray drying of aqueous solutions, as well as the production of
microporous drug releasing devices via foaming, will be highlighted in this review. Development
and strategies to control and optimize the particle morphology, drug loading, and yield from the
major processes will also be discussed.
Keywords: supercritical carbon dioxide; microencapsulation; microporous foam; supercritical drying;
supercritical anti-solvent
1. Introduction
Well-established processes using supercritical CO2 in pharmaceutical applications include
micronization by RESS (rapid expansion of supercritical solutions), SAS (supercritical antisolvent),
or ScMM (supercritical melt micronization), microencapsulation via co-precipitation (in RESS,
SAS, supercritical spray drying, etc.), active ingredient coating (spray coating, supercritical CO2
fluid bed coating, etc.), sterilization (due to microbial inactivation properties of pressurized CO2),
biopolymeric microporous foam/sponges (supercritical foaming, supercritical impregnation, etc.).
Many review and research articles have been published on the topic of using supercritical fluid
techniques for the development of drug delivery [1–7], biomedical and pharmaceutical formulations
or devices [8,9]. Supercritical fluid can be used in many different ways to produce microencapsulated
and nanoencapsulated products based on the properties of the active ingredient, coating material, and
suitable solvent (if any) used.
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The selection of processing technique with supercritical CO2 for biopolymers depend greatly
on the interaction of the supercritical CO2 with the active ingredient, coating material of interest,
and suitable solvent. In biopolymeric drug delivery systems, the interaction of the polymer with
supercritical CO2 plays an important role in the selection of the supercritical process. For instance,
polylactide (PLA) is a suitable candidate for SAS, but not RESS, as it is not easily soluble in supercritical
CO2 [10,11]. On the other hand, polylactide-co-glycolide (PLGA) has a low glass transition temperature
(Tg), and the further depression of its Tg in the presence of supercritical CO2 makes it difficult to
produce discrete free-flowing powders via the SAS process. However, this property of PLGA makes it
suitable for the production of microporous polymeric foams with very low residual organic solvent
content, allowing the production of microporous drug-releasing polymeric foams that can be used as
implant and scaffold material [12–14].
Well-established methods for drug microencapsulation and nanoencapsulation for drug delivery
include solvent evaporation, emulsion techniques, spray drying, and electrospray. Due to its attractive
properties as a clean and green solvent for processing drugs and biopolymers, supercritical CO2
processing has been regarded as an important option for the production of microencapsulated drug
delivery devices [15].
The role of supercritical CO2 (as a solvent, antisolvent, or solute) in particle design,
pharmaceutical ingredient processing, and composite particle production has been evaluated by earlier
reviews [6,9,16–18]. In a more recent review by Padrela et al. [19], the production of nanoparticle
and nanocrystals via supercritical carbon dioxide was evaluated with a comprehensive description
of the selection criteria of different methods based on the properties of the active ingredient. This
review will focus on the applications where the active ingredient is encapsulated in microsized,
nanosized, or microstructured formulations with applications for pharmaceutical or drug delivery.
This paper aims to provide the reader with a comprehensive review of the currently available
options to design and produce microencapsulated and nanoencapsulated formulations ranging from
microparticles to nanoparticles, and including recent developments such as fluidized bed coating
using supercritical CO2 and the production of drug-releasing three-dimensional microporous foam
for pharmaceutical applications. The discussion will introduce readers to different supercritical fluid
processing techniques that utilize the favorable and versatile properties displayed by supercritical
CO2, with an understanding of the underlying mechanism behind each method, and the modifications
applied to improve the particle size, morphology, and process efficiency.
2. Supercritical Carbon Dioxide Processing Systems
Depending on the active ingredient or drug compound of interest, the type of formulation required
(e.g., selection of suitable coating material for desired release profile), and the morphology of the final
encapsulated product, it is possible to modify the configuration of the supercritical fluid system to
perform different processes, as shown in our earlier studies where experiments for SAS [10,11,20],
SAS with enhanced mass transfer (SAS-EM) [10], supercritical foaming [12–14,21], and supercritical
drying [22] were performed with a custom-built supercritical fluid system.
The main sections for a supercritical CO2 unit for drug delivery production include:
(i) a high-pressure CO2 delivery system; (ii) a secondary high-pressure delivery system; (iii) a
high-pressure vessel(s)/high-pressure chamber(s); (iv) a product separation/collection/purification
system. The basic equipment required for supercritical CO2 processing include: (1) a compressed
liquid CO2 cylinder (preferably with a dipstick); (2) high-pressure liquid pumps for the delivery of
CO2 to supercritical pressure, and for co-solvents or solutions to be delivered and in contact with
high-pressure CO2; (3) chillers for liquefying, or ensuring that the CO2 at the pump head is in a
liquid state; (4) high-pressure chambers/vessels that need to be designed according to specifications
of high-pressure vessels with fittings and tubings rated for high-pressure applications (from HIP,
Swagelok etc.); (5) pressure controllers (either automated back-pressure regulators or back-pressure
valves; (6) product separation units, such as flash vessels, cyclone separators for solid–fluid separation,
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solid filter units, a zeolite-packed bed for removing moisture from water-saturated supercritical CO2;
(7) heaters/coolers for temperature control at various stages of the process, and (8) a recirculating
pump (if the CO2 is recycled). A detailed summary of supercritical fluid particle formation in the
pharmaceutical industry and representative vendor for supercritical fluid equipment and accessories
can be found in the work of Vemavarapu et al. [23].
3. Role of Supercritical Carbon Dioxide in Microencapsulation and Nanoencapsulation
CO2 has relatively accessible critical conditions of 73.8 bar and 31.1 ◦C. Its low critical temperature
allows processes to be developed at close to ambient temperatures (e.g., at 35 ◦C). Other favorable
qualities of supercritical CO2 include its non-toxic and non-flammable nature, gas-like viscosity,
liquid-like density with enhanced solubility, microbial inactivation abilities, and relatively low cost.
Figure 1 summarizes the properties of supercritical CO2, which allow it to be applied for various
microencapsulation and nanoencapsulation processes. The selection of the processing techniques
used for microencapsulation and nanoencapsulation depends on the materials and thermodynamic
properties of the active ingredient, the coating material, and any suitable co-solvent that is available.
Other criteria in the selection of a suitable supercritical fluid technique include the desired formulation
(size, morphology, release profiles, porosity, etc.).
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The role of supercritical CO2 as a solvent, antisolvent, solute, drying medium, and foaming agent
will be evaluated and explained in the following sections.
3.1. Supercritical Carbon Dioxide as a Solvent
At supercritical conditions, CO2 has enhanced solubility for substances such as essential oils, active
ingredients in plants and natural products [24–26], small molecular weight non-polar compounds,
and low-molecular weight biopolymers. As supercritical conditions can be reached even at low
temperature, this makes supercritical CO2 very attractive as a solvent, and it has been applied in
numerous studies for the extraction of active ingredients (e.g., for caffeine decaffeination, essential oil
extraction, active ingredient encapsulation, etc.).
Rapid Expansion of Supercritical Solutions (RESS)
In the rapid expansion of supercritical solutions (RESS), the active ingredient and coating
ingredient are dissolved in a supercritical fluid (acting as a solvent). The supercritical fluid solution
containing the solutes is maintained at high pressure before expanding across a fine throttling device,
such as a capillary or orifice nozzle [27–29]. At this point, supersaturation occurs, leading to the
desolvation of the coating material, which is then deposited around the active ingredient, forming
microcapsules (Figure 2). In active pharmaceutical ingredient (API) encapsulation applications,
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the microcrystalline pharmaceutical dominates the core of the particles, while the slower precipitating
polymer coats the surface. The advantages of RESS include its capacity for a wide range of inorganic,
organic, and polymeric materials, low-temperature operation, and single-step processing [30]. Table 1
shows some examples of bioproducts that are encapsulated using the RESS process. The prerequisite
of this process is that both the active ingredient and the coating material must be very soluble in
supercritical fluids. This typically applies to lower molecular weight polymers and small active
ingredients such as non-polar small molecule compounds.
The RESS of polymer solutions in CO2 has been limited by low polymer solubility at temperatures
below 80 ◦C [31]. To overcome this limitation, the RESS process can be modified with the application of
a co-solvent. The solubility of the polymers in CO2 increases significantly with low molecular weight
alcohols as co-solvents, such as ethanol and methanol [32]. The modified process is termed as rapid
expansion of supercritical solutions with a non-solvent (RESS-N). In the RESS-N process, a suspension
of the active ingredient in a co-solvent containing CO2 and a dissolved polymer is sprayed through a
nozzle to atmospheric pressure. The co-solvent, in pure form, is a non-solvent for the polymer, and is
only sparingly soluble in the polymer particles that are produced during expansion [33]. Therefore,
the particles do not agglomerate after expansion, since there is no swelling of polymer products. The
modified RESS has been applied to the encapsulation of proteins [32] and medicines [34], as shown
in Table 2. The polymer-coating thickness, mean particle diameter, and particle size distribution of
microcapsules could be controlled by changing the feed composition of the polymer [32,34].
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Table 1. Examples of bioproducts encapsulated using the RESS process.
Active Ingredient Coating Material Particle Size and Morphology Reference
Coenzyme Q10
Poly(ethylene glycol) (PEG)
Polylactic acid (PLA)
2–10 µm
PEG: Uniform and small spheres
PLA: Spherical agglomerated microparticles
[27]
Felodipine PEG4000 2–6 µmGel-like irregular mass [28]
Melatonin Liposomes 66 nmRound or oval microspheres with uniform distribution [29]
Naproxen PLA 10–90 µmMicrospheres with agglomerates [30]
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Table 2. Examples of microencapsulation applications by the rapid expansion of supercritical solutions
with a non-solvent (RESS-N).
Active Ingredient Coating Material Co-Solvent Reference
Proteins (lysozyme and lipase)
PEG4000, PEG6000, PEG20000,
poly(methyl methacrylate)
(PMMA), PLA,
polyglycolide-co-lactide (PGLA),
and PEG- poly(propylene glycol)
(PPG)-PEG triblock copolymer
Ethanol/methanol/propanol/
acetone/toluene [32]
P-acetamidophenol,
acetylsalicylic acid,
1,3-dimethylxanthine, flavone,
and 3-hydroxyflavone
PEG4000, PEG6000, PEG20000,
PLA, PMMA, ethyl cellulose, and
PEG-PPG-PEG triblock copolymer
Ethanol/methanol/propanol/
acetone/toluene [34]
3.2. Supercritical Carbon Dioxide as an Anti-Solvent
The limitations of RESS can be overcome by a supercritical antisolvent (SAS), which utilizes
the high miscibility of supercritical CO2 with organic solvents; this can be used to dissolve both
the active ingredient and the coating material of interest. When the organic solution is introduced
into supercritical CO2, the CO2 rapidly extracts the organic solvent from the solution jet, leading to
the rapid precipitation of the composite product. The resulting product will be an active ingredient
distributed in the matrix of the coating material.
3.2.1. Supercritical Antisolvent (SAS)
The supercritical antisolvent (SAS) technique is one of the most versatile [35] and widely
researched techniques using supercritical CO2 for micronization and microencapsulation [10,35–52].
The process can be applied to a wide range of compounds and biopolymers that have limited
solubility in supercritical CO2. The SAS process has been applied in micronizing APIs, and has
been shown to produce improve bioavailability and the solubility of hydrophobic drug compounds
by size reduction and the control of crystal morphology [41]. Different biopolymeric morphologies
(threads, sponges, and microparticles) can also be achieved from SAS processes [49]. Although the SAS
is favorable for the production of formulations for hydrophobic drugs with low bioavailability and
poor aqueous solubility [41,44,47,53], the encapsulation of hydrophilic compounds [40,54] have also
been demonstrated by dispersing the hydrophilic drug in the organic solution. The co-precipitation
produces monolithic matrix systems rather than reservoir systems, and the drug release profiles
typically follow diffusion-controlled or polymer degradation mechanisms [10].
Typically, SAS operates by the continuous and simultaneous injection of the organic solution
with supercritical CO2 into a chamber with supercritical CO2 via a nozzle. The mechanism of
particle formation using SAS is illustrated in Figure 3. The means of contact between the solution
and CO2 can vary in different versions of the process, leading to several variations in the SAS
process such as the PCA (precipitation from compressed antisolvent) [55], ASES (aerosol solvent
extraction system) [50], SEDS (solution-enhanced dispersion by supercritical fluids) [42], and SAA
(supercritical-assisted atomization) [53]. In the SEDS process, the solution and supercritical CO2
were introduced into the precipitation vessel simultaneously via a co-axial nozzle. This enhanced the
dispersion and contact between the solution and supercritical CO2. Chattopadhyay and Gupta [56]
designed a method of combining ultrasonic mixing within a SAS chamber to achieve nanoparticle
and nanoencapsulations [54] via an enhanced mixing mechanism between supercritical CO2 and the
organic solution. These processes were designed and developed to achieve better understanding and
control of the SAS process in order to obtain particles with desired characteristics [43,48,57]. In addition,
numerous studies were also carried out to understand the underlying mechanism during SAS, such
as the jet break-up phenomena [10,20,58,59], the role of mass transfer [46,56], the solvent–antisolvent
interaction behavior, etc.
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3.2.2. Supercritical Fluidized Bed Coating
Fluidized bed drying and coating processes have been well established as scalable means of
obtaining coated APIs (e.g., Wurster fluid bed coating) [60]. The use of supercritical CO2 as the
fluidizing medium for core particles as well as the drying agent or antisolvent to remove the moisture
or solvent respectively from core particles coated with the coating material solution is of great interest,
as it allows the coating to be performed in oxygen-free and low-temperature conditions.
In the studies by Subramaniam et al. [61], a Wurster-type coater employing near-critical CO2
as an antisolvent for solvent removal from coated particles was developed. Studies on particle
fluidization with supercritical CO2 have shown that conventional correlations for fluidization can be
applied for supercritical fluids for the prediction of minimum fluidizing and terminal velocities [62].
Supercritical fluidized bed coating utilizes the fluidization of solid core particles using supercritical
CO2 as a fluidizing medium and at the same time, a solution with the coating material will be
sprayed onto the fluidized particles. The supercritical CO2 plays the role of a drying medium
(for aqueous solutions) or an antisolvent (for organic solutions) to dry the fluidized particles in the
bed. The coating of API and ingredients such as curcumin has been demonstrated using supercritical
fluid coating processes [61,63–65]. This technique has promising development for the production of
controlled multi-layered coatings on APIs to achieve formulations with desired sustained release or
surface properties.
3.2.3. Supercritical Fluid Extraction of Emulsions (SFEE)
One of the limitations of RESS and SAS in microencapsulation is the processing of polymers that
tend to plasticize in the presence of supercritical CO2, including the class of commonly used amorphous
polymers in drug delivery (including PLGA, polymethylmethacrylate (PMMA), and polycaprolactone
(PCL)) [66]. To overcome the above-mentioned limitations, Chattopadhyay and Shekunov [66]
presented the supercritical fluid extraction of emulsions (SFEE) technique. In this technique, the active
ingredient and polymer is dissolved in organic solvent, and the organic phase and the organic
solution are then emulsified with aqueous phase to form an oil/water emulsion. Supercritical CO2
is used to extract the organic solvent from the emulsion, leading to the supersaturation of the active
ingredient and polymer in the aqueous phase, and resulting in the precipitation of the active ingredient
and polymer. The precipitated microencapsulation or nanoencapsulation particles are subsequently
collected from the aqueous phase. Figure 4 illustrates the general schematic representation of the
SFEE process.
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An important feature of the SFEE process is the ability to form nearly monodisp rse microenca sulates
or nanoencapsulates. Table 3 shows examples of microencapsulated and nanoencapsulated formulations
produced using the SFEE process. Active ingredients ranging from low-bioavailability hydrophobic
drugs [66–68] to model proteins [69] and even oils [70] can be encapsulated using this method.
Table 3. Examples of microencapsulates and nanoencapsulates by the SFEE process.
Active Ingredient t rial Particle Size andMorphology Reference
Indomethacin Polylactide-co-glycolide (PLGA)/Eudragit RS <1 µmSpherical [66]
Lysozyme PLGA ~0.1–1 µmSpherical [69]
Ketoprofen PLGA ~0.1–1 µmSpherical [66,68]
Vitamin E Polycaprolactone (PCL) ~10–300 nmSpherical nanoparticles [71,72]
Medroxyprogesterone Poly(3-hydroxybutirate-co-3-hydroxyvalerate)(PHBV)
~0.1–1 µm
Spherical [67]
Omega-3-rich fish oil PCL ~10–10 nmSpherical nanoparticles [70]
3.3. Supercritical Carbon Dioxide as a Drying Agent
CO2 has an increased ffinity for water at conditions above its critical point (31.1 ◦C, 73.8 bar) [73],
which makes it good c ndidate for drying aqueous solutions and wet samples that otherwise cannot
be dried by traditional drying techniques due to their thermal sensitivity and oxidation. Supercritical
CO2 has been found to be a good drying medium for food matrices [74–77], aerogels [78–82], and other
natural products [22] due to its offer of low processing temperatures.
Supercritical Spray Drying
Supercritical spray drying refers to the spraying of an aqueous solution into an excess of
supercritical CO2. Similar to hot air spray-drying, supercritical CO2 spray drying utilizes the increased
solubility of CO2 with water at supercritical conditions. The break-up of the aqueous solution into
very tiny droplets (with high surface area to volume ratios) enhances the mass transfer of water into
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the supercritical CO2 in the drying chamber and therefore, the water is removed continually from the
drying chamber. Figure 5 shows the schematic representation of the supercritical spray-drying process.
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This technique is suitable in the microencapsulation for ulations here the coating material is a
water-soluble mat rial (such as sugars, starches, maltodextrin, etc.), which will form the aqueous phase
that will be sprayed into supercritical CO2. The active ingredie t can be dissolved in the sam aqu ous
phase (pr teins or hydr philic compounds) or distributed in the aq eous phase via mulsification (oil,
fatty acids, or organic solution) or suspension (fine solid particles). One promising application of the
process is the encapsulation of oils to produce free-flowing oil encapsulated powders [51,83–85],
which can be applied in the nutraceutical market for oil (polyunsaturated fatty acids (PUFAs),
docosahexaenoic acids (DHAs), eicosapentaenoic acid (EPAs) etc.). The production of a water-insoluble
phospholipid-rich oil has been reported in the World Intellectual Property Organization (WO) patent
application (WO 2010014011 A1) [86], where a two-step supercritical spray drying followed by a
supercritical antisolvent procedure (for coating) was performed to obtain a microencapsulated oil with
a non-soluble coating. Units ranging from four liters to 10 liters have been developed for the laboratory
to demonstration scale of supercritical spray drying, where co-axial nozzle was sed to i troduce
and break up the aque us olution into finely rsed droplets using scCO2 as the dispersing agent
and drying medium [87].
3.4. Supercritical Carbon Dioxide as a Solute
Due to its low viscosity and high diffusivity, supercritical CO2 can diffuse very efficiently into
solutions, polymer melts, and also fatty acids. Using this property of supercritical CO2, strategies for
producing microencapsulated particles from an aqueous solution can be achieved.
Particles from Gas-Saturated Sol tions (PGSS)
In particles from gas-saturated solutions (PGSS), supercritical CO2 acts as a solute, diffusing
and dissolving into a melt or solution, forming a gas-saturated solution. The solution will then be
expanded via a nozzle into a spray chamber at atmospheric pressure. The CO2 gas then leaves the
gas-saturated polymer/fat droplets and also during expansion, the temperature of the mixture reduces
drastically due to the Joule–Thomson effect, hence causing the polymer solidification [88]. A similar
process termed as supercritical melt micronization (ScMM) has been developed for the micronization
of fats (such as hard fats or milk fats) [89–92]. For microencapsulation application, the PGSS process
can be used for water-soluble active ingredients and coating materials. The PGSS drying process
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(Figure 6) involves mixing an aqueous solution, containing the active material and wall material, and
saturating the solution with supercritical CO2. Subsequently, the gas-saturated solution is expanded
via a nozzle into a spray chamber at atmospheric pressure. This leads to the encapsulation of key
compounds by the co-precipitation of the coating and core materials. PGSS holds several advantages
over conventional methods such as coacervation, spray-drying, and emulsion techniques due to its
mild operating conditions and its ability to produce solvent-free and homogenous products. This
is especially beneficial in preserving the stability of ingredients such as essential oils [93,94] and
heat-sensitive virus proteins [95], where elevated temperatures and organic solvents could cause
negative interactions. Table 4 shows examples of bioproducts encapsulated via PGSS.
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Table 4. Examples of bioproducts encapsulated using the PGSS process.
Active Ingredient Coating Material Particle Size and Morphology Reference
β-carotene
Soy lecithin 10–500 µmAgglomerates of partially fused spheres [96]
Polycaprolactone (PCL)
(CAPA 2403D and CAPA 6100)
CAPA 2403D: 110–130 µm
CAPA 6100: 270–650 µm
Flat or sphere-like particles attached and
agglomerated by long filaments of polymer
[97]
Coffee oil Polyethylene Glycol (PEG)
78 µm
Spherical shapes of various sizes to
amorphous shapes
[98]
Cydia pomonella granulovirus
Palm oil-based fat: 77%
Lecithin-based urfactant: 9%
Modifie titanium oxide and
benzophenone derivative UV
protectants: 2%
<85 µm
Almost spherical particles were obtained [95]
Lavandin es ential oil
PEG 9000 30–10 µmSpheres and needl s [93]
Soy lecithin 1.4–24.8 µmDry and fine but aggregated particles [94]
Limonene Modified starch
60–90 µm
Spherical shapes with few broken shapes
smaller than the others
[99]
Omega-3 polyunsaturated
fatty acids and
astaxanthin-rich salmon oil
PEG 6000
67.26–165.81 µm
Irregular spherical shapes to amorphous
shapes of various sizes
[100]
Quercetin Soy lecithin and Pluronic L64®
0.138–0.158 µm
Complete encapsulation of
amorphous quercetin
[101]
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3.5. Supercritical CO2 as a Foaming Agent
In the production of microporous biopolymeric structures via supercritical CO2 foaming,
supercritical CO2 is first contacted with the polymer in a high-pressure chamber. The supercritical
CO2 diffuses into the polymer matrix, causing the glass transition temperature (Tg) of the polymer to
be lowered, and forming a solution of the polymer with CO2. On depressurization, the CO2 leaves the
polymer–CO2 mixture and the polymer vitrify, leaving a microporous structure on the polymer. In this
case, CO2 actually acts both as a solute and a foaming agent. This section will focus of the role of CO2
as a foaming agent to produce the microporous structure within the biopolymer matrix as a potential
drug delivery platform for pharmaceutical applications.
The supercritical CO2 foaming of biopolymers is an attractive method for the production of
microporous constructs for biomedical applications. Using supercritical carbon dioxide as a foaming
agent, the use of organic solvents for the fabrication of the PLGA foams can be minimized or avoided,
resulting in a zero to low-residual solvent product. The pore size and morphology of the PLGA foams
can be controlled by factors such as the operating conditions of the foaming process (temperature,
pressure), the rate of depressurization, and the nature of the selected co-polymer (polymer functional
end groups, lactic to glycolic ratio, molecular weight, etc.). The encapsulation of active ingredients
ranging from protein, anticancer drugs, chitosan, etc. has been demonstrated for potential applications
for implant drug delivery for chemotherapy, scaffold material for cell cultivation, new carriers for
DNA delivery, etc.
Strategies for encapsulating the active ingredient or drug in a microporous biopolymeric matrix
include a single-step impregnation process, as presented by Cabezas et al. [102,103] and via a two-step
encapsulation supercritical foaming process [12,13]. The supercritical foaming of biodegradable
polymers such as polylactic-co-glycolic acid (PLGA) has potential applications for drug delivery and
biomedical implants.
3.5.1. Single-Step Impregnation and Foaming
In the single-step impregnation and foaming process to produce microporous biopolymeric foams
with encapsulated ingredients, supercritical CO2 acts both as a solvent for the active ingredient and as
a solute in infiltrating the polymer matrix. This is a promising technique where a residual solvent-free
implant can be obtained at low processing temperatures, which can be particularly important for
thermally-labile active ingredients [104]. Indomethacin [103] and 5-fluorouracil [102] have been
encapsulated in microporous polymer foams using the impregnation and foaming processes.
One of the current limitations of this method is that the drug loading in the polymeric
material is limited by the solubility of the solute in the supercritical CO2. To achieve higher drug
loading and encapsulation efficiencies, and to be able to encapsulate a range of different active
ingredients (hydrophobic, hydrophilic, etc.), a two-step process can be considered for the design of
desired formulations.
3.5.2. Two-Step Drug Encapsulation and Foaming
The two-step process of drug encapsulation and foaming involves first obtaining a drug-encapsulated
polymer matrix via methods such as solvent casting [105], spray drying [12,13], or emulsion
methods [21]. The drug-encapsulated polymer then undergoes supercritical gas foaming to obtain a
microporous polymeric structure with the drug encapsulated in the polymer matrix. The encapsulation
of the active ingredient in the polymer matrix is not limited by its solubility in supercritical CO2, as the
precursor drug-loaded polymer can be achieved by other well-established encapsulation methods
such as solvent evaporation, emulsification methods, or spray drying (Figure 7).
In this method, most of the drug encapsulated in the polymer prior to foaming will remain in
the microporous foamed product [12,21]. One drawback of the two-step encapsulation and foaming
process is that an organic solvent is typically used in the first step. However, as CO2 is able to
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penetrate into the polymer matrix, the residual solvent is also removed by the CO2 during the
foaming process, leaving behind a product with very low residual solvent content [12]. In our
earlier studies, it was observed that the residual solvent in spray-dried particles of paclitaxel-loaded
PLGA (using dichloromethane as the solvent) is reduced significantly after the CO2 foaming
process [12]. Formulations encapsulating chitosan [13], paclitaxel [12], curcumin, and gentamicin [21]
for applications as implants or scaffolds have been demonstrated using this method. The active
ingredient will be encapsulated within the matrix of the microporous structure, and drug release
will follow a diffusion mechanism and/or follow the degradation of the polymer matrix [12,106].
The microporous structure as a drug delivery device is particularly useful for the delivery of drugs
with low bioavailability and low solubility. The high surface to volume ratio of the formulation
enhances the drug release by diffusion [12,106].
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4. Conclusions and Future Perspectives
The favorable and tunable properties of supercritical 2 make it a very attractive option in
processing products for p ar ace tical a licati s, artic larly regarding the microencapsulation
and nanoencapsulation of drugs or active ingredients for sustained or targeted releas . The process that
is selected depen s on the properties of th active ingredient an coating material of interest, such as the
solubility, hydrophobicity, molecular weight, gl ss transition temperatures, cryst llinity, etc. The SAS
method is very useful in the micronization and formation of a orph us drug particles. However,
not all biopolymers can be pro essed using SAS due to the interactio of supercritical CO2 with the
polymer. The SFEE technique prov des an elegant altern tive o the SAS process, which can be used to
proce s a wider range of drug delivery polymers such as PCL, PLGA, HBV, etc. Recent developm ts
in combining a fluidizat on co ting with SAS or supercritical drying also offer opportunities f r the
more spec fic design of a controlled-rel ase formulation. The supercritical foaming technique allows
three-dimensional microporous polymeric structures with encapsulated drugs to be produced. This
provides opportunities to develop controlled release scaffold or implant material .
The versatility and compatibility of supercritical fluid processing techniques also allow smart
coating materials such as cyclodextrins to be used as encapsulating agents, which is useful in the
nanoencapsulation and microencapsulation of flavors and aromas [107–111]. Formulations with
cyclodextrins can also be produced for drug delivery applications, as demonstrated by Adeoye et al.
for ibuprofen/hydroxypropyl-γ-cyclodextrin inclusion complexes via a supercritical CO2-assisted
spray-drying process [112]. In our opinion, it will be important to develop integrated supercritical
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CO2 processing strategies that combine multiple steps in pharmaceutical processing. The highly
tunable solvent properties of supercritical CO2 can be explored to develop processes for particle
formation or encapsulation, the removal of impurities and residual solvents, and the separation and
recovery of organic solvents in a single process train, which can help intensify the pharmaceutical
production processes [16]. The offer of a “greener” route [16] using little to no organic solvents during
pharmaceutical formulation processing, and a “cleaner” product whereby the efficient removal of the
residual solvent by supercritical CO2, and its microbial inactivation abilities, makes supercritical fluid
technologies very favorable for pharmaceutical manufacturing industries.
From the available literature, it can be seen that the mechanism and various configurations of
supercritical CO2 processes has already been studied extensively, providing a well-established database
for both thermodynamic (density, viscosity, solubility at different temperature, pressure conditions,
etc.) [113–116] and fluid dynamic behavior (jet break-up, mass transfer, etc.) [58,59]. A focus on the
research and development of systems in compliance with pharmaceutical manufacturing practices,
with a clear evaluation of health and safety guidelines and considerations for operation, and complete
with a techno-economic model of the technology, will help realize its potential for implementation and
scale-up in pharmaceutical processes in the near future.
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